2021 Special Committee on Federal 340B Drug Program

Senate	House
Senator Renee Erickson, Vice Chairperson Senator Beverly Gossage Senator Richard Hilderbrand Senator Kristen O'Shea Senator Jeff Pittman Senator Mary Ware	Representative Susan Concannon, Chairperson Representative John Barker Representative Will Carpenter Representative Brenda Landwehr Representative Vic Miller Representative Sean Tarwater Representative Kathy Wolfe Moore

Kansas Legislative Research Dept.	Office of Revisor of Statutes
Megan Leopold Melissa Renick LeAnn Thone	Scott Abbott Amelia Kovar-Donohue Eileen Ma

Committee Assistant

Study Topic

The Committee is directed to:

Review the 340B Drug Pricing Program, with the objective of gaining a better understanding of how the program is implemented in Kansas and the experience of participating entities.

Topics for review should include:

Federal requirements of the program;
The role qualifying 340B providers, pharmacies, and pharmacy benefit managers play in the program;
The fiscal impact of such program on all participants;
Any federal or state law changes affecting such program;
Any recent marketplace developments of interest; and
The impact of such program on health care payers.

[Note: Provisions in 2021 SB 159 [Section 20 (c)] directed the Legislature to create an interim study committee on the federal 340B program. The law specified the Legislative Coordinating Council would appoint a special committee comprised of 13 members, with its chairperson appointed by the Speaker of the House of Representatives.]

Approved Meeting Days: 2 days